Trial · NCT06613854
Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
NCT06613854, Phase 4, Recruiting, University Medical Centre Ljubljana
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes. Trials, record NCT06613854. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06613854
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
- NCT number
- NCT06613854
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 90 participants, estimated
- Lead sponsor
- University Medical Centre Ljubljana
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Oral semaglutide, Empagliflozin 10 mg
- First posted
- 2024-09-26
- Last updated
- 2026-04-30
Source ClinicalTrials.gov
Registered outcomes63
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time in Range (TIR) | Period of 14 days prior to last study visit (week 26) | Defined as the time (or percentage of measurements) when the glucose value in the interstitial fluid is in the range of 3.9-10.0 mmol/L. Assesment by Continuous Glucose Monitoring system FreeStyle Libre 2 (in % or in hours and minutes). |
| Secondary | Absolute Change in Time in Range (TIR) | Baseline (week 0) and last study visit (week 26) | Assesment by Continuous Glucose Monitoring system FreeStyle Libre 2 (in % or in hours and minutes). |
| Secondary | Absolute Change in Glycated hemoglobin (HbA1c) | Baseline (week 0) and last study visit (week 26) | Assessment by biochemical methods (in %) |
| Secondary | Time above Range (TAR) | Last study visit (week 26) | Defined as the time (or percentage of measurements) when the glucose value in the interstitial fluid is above 10.0 mmol/L. Assesment by Continuous Glucose Monitoring system FreeStyle Libre 2 (in % or in hours and minutes). |
| Secondary | Time below Range (TBR) | Last study visit (week 26) | Defined as the time (or percentage of measurements) when the glucose value in the interstitial fluid is below 3.9 mmol/L. Assesment by Continuous Glucose Monitoring system FreeStyle Libre 2 (in % or in hours and minutes). |
| Secondary | Time above Range (TAR) - Level 1 Hyperglycemia | Last study visit (week 26) | Defined as the time (or percentage of measurements) when the glucose value in the interstitial fluid is in the range of 10.1-13.9 mmol/L. Assesment by Continuous Glucose Monitoring system FreeStyle Libre 2 (in % or in hours and minutes). |
| Secondary | Time above Range (TAR) - Level 2 Hyperglycemia | Last study visit (week 26) | Defined as the time (or percentage of measurements) when the glucose value in the interstitial fluid is above 13.9 mmol/L. Assesment by Continuous Glucose Monitoring system FreeStyle Libre 2 (in % or in hours and minutes). |
| Secondary | Time below Range (TBR) - Level 1 Hypoglycemia | Last study visit (week 26) | Defined as the time (or percentage of measurements) when the glucose value in the interstitial fluid is in the range of 3.0-3.8 mmol/L. Assesment by Continuous Glucose Monitoring system FreeStyle Libre 2 (in % or in hours and minutes). |
| Secondary | Time below Range (TBR) - Level 2 Hypoglycemia | Last study visit (week 26) | Defined as the time (or percentage of measurements) when the glucose value in the interstitial fluid is below 3.0 mmol/L. Assesment by Continuous Glucose Monitoring system FreeStyle Libre 2 (in % or in hours and minutes). |
| Secondary | Time in Tight Range (TITR) | Last study visit (week 26) | Defined as the time (or percentage of measurements) when the glucose value in the interstitial fluid is in the range of 3.9-7.8 mmol/L. Assesment by Continuous Glucose Monitoring system FreeStyle Libre 2 (in % or in hours and minutes). |
1 to 10 of 63Source ClinicalTrials.gov
See all 63 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06613854
GET https://conductscience.org/api/trials/v1/NCT06613854/registered?page=2